Pharma Focus Asia

PharmaTher Holdings Announces FDA Grant of Orphan Drug Designation to KETARX™

Friday, February 03, 2023

PharmaTher announced that the U.S. Food and Drug Administration (“FDA”) has granted orphan drug designation to KETARX™ (racemic ketamine) for the treatment of Rett Syndrome, a rare genetic neurological disorder.

Phase 2 clinical study results to support proposed Phase 3 development of KETARX™ (ketamine) to treat Rett Syndrome for FDA approval via the 505(b)(2) regulatory pathway.

Ketamine is subjected to a Phase 2 clinical trial (NCT03633058) for Rett syndrome. Unpublished results from the study will be evaluated to support a potential Phase 3 clinical study and obtain FDA agreement on a regulatory plan for approval via the 505(b)(2) regulatory pathway.

The potential of KETARX™ for rare disorders, and the addition of the Rett syndrome programme to the four FDA-approved orphan drug designations strengthens position in leading the advancement of ketamine for unmet medical needs in mental health, neurological and pain disorders.

Orphan drug designation has qualified ketamine for certain benefits and incentives, including seven years of marketing exclusivity if regulatory approval is ultimately received for the designated indication, potential tax credits for certain clinical drug testing costs, eligibility for orphan drug grants, and the waiver of the FDA New Drug Application filing fee of approximately $2.4 million.

magazine-slider-imageCytiva - Supor Prime filtersMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024